Ion Channel Focus ChanTest specializes in ion channel and GPCR safety testing and screening, serving global pharma and biotech clients. This positions them as a specialized CRO with deep domain expertise, suggesting cross-sell opportunities to companies expanding ion channel programs or requiring regulatory-compliant GLP and non-GLP services.

Comprehensive Cardiac Safety The company maintains a broad library of validated ion channel cell lines and a pre-clinical cardiac risk assessment portfolio, which is among the most comprehensive in the market. This can be leveraged to win bids from sponsors needing robust cardiac safety profiling as part of early drug screening or IND-enabling studies.

Trusted Provider ChanTest has earned recognition as the most trusted and most used fee-for-service provider for ion channel screening in HTStec surveys since 2006. This longstanding credibility can be used in prospective client discussions to mitigate perceived risk and differentiate from competitors.

Global RFP Fit With a history of testing compounds for over 300 global pharma and biotech companies, ChanTest demonstrates scale and experience that aligns with large and mid-size sponsors seeking established CRO partners for reliable, high-value ion channel and GPCR services.

Growth Scenarios Revenue guidance indicates a lean-sized operation with potential for expanded services, regional partnerships, or expanded GLP/non-GLP offerings. Target opportunities include mid- to large-cap pharma companies expanding ion channel programs, as well as biotechs needing specialized safety testing to accelerate development timelines.